Immunohistochemical characterization of subtypes of male breast carcinoma

Breast Cancer Research

Volumn 11, Issue 3, 2009, Pages

  Ge, Yimin ^a   Sneige, Nour ^b   Eltorky, Mahmoud A ^c   Wang, Zhiqin ^c   Lin, E ^b   Gong, Yun ^b   Guo, Ming ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROGESTERONE RECEPTOR; HER2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER HORMONE THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MALE; MALE BREAST CARCINOMA; MASTECTOMY; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; BIOSYNTHESIS; BREAST TUMOR; CLASSIFICATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY;

AGED; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KERATIN-5; KERATIN-6; MALE; MIDDLE AGED; NF-KAPPA B; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 74049140876     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2258     Document Type: Article

References (34)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. CA: A Cancer Journal for Clinicians 2005, 55:10-30. 10.3322/canjclin.55.1.10, 15661684.
2. Weiss JR, Moysich KB, Swede H. Epidemiology of male breast cancer. Cancer Epidemiol Biomarkers Prev 2005, 14:20-26. 10.1158/1055-9965.EPI-05-0414, 15668471.
3. American Cancer Society (2009): What are the key statistics about breast cancer in men?. , http://www.cancer.org/docroot/CRI/content/CRI_2_4_1X_What_are_the_key_statistics_for_male_breast_cancer_28.asp?rnav=cri
4. Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN. Breast carcinoma in men: a population-based study. Cancer 2004, 101:51-57. 10.1002/cncr.20312, 15221988.
5. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874. 58566, 11553815, 10.1073/pnas.191367098.
6. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brown PO, Børresen-Dale AL, Botstein D. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100:8418-8423. 166244, 12829800, 10.1073/pnas.0932692100.
7. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003, 100:10393-10398. 193572, 12917485, 10.1073/pnas.1732912100.
8. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, Rijn M, Perou CM. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367-5374. 10.1158/1078-0432.CCR-04-0220, 15328174.
9. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295:2492-2502. 10.1001/jama.295.21.2492, 16757721.
10. Iwase H, Itoh Y, Kuzushima T, Yamashita H, Iwata H, Toyama T, Hara Y, Kobayashi S. Simultaneous quantitative analyses of c-erbB-2 protein, epidermal growth factor receptor, cathepsin D, and hormone receptors in breast cancer. Cancer Detect Prev 1997, 21:29-35.
11. Pirinen R, Lipponen P, Syrjanen K. Expression of epidermal growth factor receptor (EGFR) in breast cancer as related to clinical, prognostic and cytometric factors. Anticancer Res 1995, 15:2835-2840.
12. Fernandez Val JF, Losada J, Arregui Murua MA, Sarria R. Cell proliferation, nuclear ploidy, and EGFr and HER2/neu tyrosine kinase oncoproteins in infiltrating ductal breast carcinoma. Cancer Genet Cytogenet 2002, 138:69-72. 10.1016/S0165-4608(02)00567-8, 12419588.
13. Toyama T, Yamashita H, Kondo N, Okuda K, Takahashi S, Sasaki H, Sugiura H, Iwase H, Fujii Y. Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers. BMC Cancer 2008, 8:309. 2612006, 18950515, 10.1186/1471-2407-8-309.
14. Gee JM, Harper ME, Hutcheson IR, Madden TA, Barrow D, Knowlden JM, McClelland RA, Jordan N, Wakeling AE, Nicholson RI. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 2003, 144:5105-5117. 10.1210/en.2003-0705, 12960029.
15. Sundvall M, Iljin K, Kilpinen S, Sara H, Kallioniemi OP, Elenius K. Role of ErbB4 in breast cancer. J Mammary Gland Biol Neoplasia 2008, 13:259-268. 10.1007/s10911-008-9079-3, 18454307.
16. Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, Chan S, Jagiello-Gruszfeld A, Kaufman B, Crown J, Chan A, Campone M, Viens P, Davidson N, Gorbounova V, Raats JI, Skarlos D, Newstat B, Roychowdhury D, Paoletti P, Oliva C, Rubin S, Stein S, Geyer CE. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008, 112:533-543. 10.1007/s10549-007-9885-0, 18188694.
17. Biswas DK, Cruz AP, Gansberger E, Pardee AB. Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci USA 2000, 97:8542-8547. 26984, 10900013, 10.1073/pnas.97.15.8542.
18. Helbig G, Christopherson KW, Bhat-Nakshatri P, Kumar S, Kishimoto H, Miller KD, Broxmeyer HE, Nakshatri H. NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem 2003, 278:21631-21638. 10.1074/jbc.M300609200, 12690099.
19. Park BK, Zhang H, Zeng Q, Dai J, Keller ET, Giordano T, Gu K, Shah V, Pei L, Zarbo RJ, McCauley L, Shi S, Chen S, Wang CY. NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat Med 2007, 13:62-69. 10.1038/nm1519, 17159986.
20. Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB, Iglehart JD. NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci USA 2004, 101:10137-10142. 454178, 15220474, 10.1073/pnas.0403621101.
21. Montagut C, Tusquets I, Ferrer B, Corominas JM, Bellosillo B, Campas C, Suarez M, Fabregat X, Campo E, Gascon P, Serrano S, Fernandez PL, Rovira A, Albanell J. Activation of nuclear factor-kappa B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients. Endocr Relat Cancer 2006, 13:607-616. 10.1677/erc.1.01171, 16728586.
22. Ahmed KM, Cao N, Li JJ. HER-2 and NF-kappaB as the targets for therapy-resistant breast cancer. Anticancer Res 2006, 26:4235-4243.
23. Singh S, Shi Q, Bailey ST, Palczewski MJ, Pardee AB, Iglehart JD, Biswas DK. Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer. Mol Cancer Ther 2007, 6:1973-1982. 10.1158/1535-7163.MCT-07-0063, 17620428.
24. Ihemelandu CU, Leffall LD, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, Adams-Campbell L, Frederick WA. Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival. J Surg Res 2007, 143:109-118. 10.1016/j.jss.2007.03.085, 17950079.
25. Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, Hewitt SM, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, Zatonski W, Cartun R, Mandich D, Rymkiewicz G, Ligaj M, Lukaszek S, Kordek R, García-Closas M. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 2007, 16:439-443. 10.1158/1055-9965.EPI-06-0806, 17372238.
26. Lanitis S, Rice AJ, Vaughan A, Cathcart P, Filippakis G, Al Mufti R, Hadjiminas DJ. Diagnosis and management of male breast cancer. World J Surg 2008, 32:2471-2476. 10.1007/s00268-008-9713-7, 18787895.
27. Wang-Rodriguez J, Cross K, Gallagher S, Djahanban M, Armstrong JM, Wiedner N, Shapiro DH. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases. Mod Pathol 2002, 15:853-861. 10.1097/01.MP.0000022251.61944.1D, 12181271.
28. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (New York, NY) 1987, 235:177-182.
29. Rudlowski C, Friedrichs N, Faridi A, Fuzesi L, Moll R, Bastert G, Rath W, Buttner R. Her-2/neu gene amplification and protein expression in primary male breast cancer. Breast Cancer Res Treat 2004, 84:215-223. 10.1023/B:BREA.0000019953.92921.7e, 15026619.
30. Joshi MG, Lee AK, Loda M, Camus MG, Pedersen C, Heatley GJ, Hughes KS. Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome. Cancer 1996, 77:490-498. 10.1002/(SICI)1097-0142(19960201)77:3<490::AID-CNCR10>3.0.CO;2-#, 8630956.
31. Willsher PC, Leach IH, Ellis IO, Bell JA, Elston CW, Bourke JB, Blamey RW, Robertson JF. Male breast cancer: pathological and immunohistochemical features. Anticancer Res 1997, 17:2335-2338.
32. Reis-Filho JS, Milanezi F, Carvalho S, Simpson PT, Steele D, Savage K, Lambros MB, Pereira EM, Nesland JM, Lakhani SR, Schmitt FC. Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. Breast Cancer Res 2005, 7:R1028-1035. 1410747, 16280056, 10.1186/bcr1341.
33. Chung HC, Kim DL, Koh EH, Kim JH, Roh JK, Min JS, Lee KS, Yang WI, Kim BS, Lee KB. Expression of prognostic factors (EGFR, ER) by immunohistochemical staining method in male breast cancer. Yonsei Med J 1991, 32:126-130.
34. Fox SB, Rogers S, Day CA, Underwood JC. Oestrogen receptor and epidermal growth factor receptor expression in male breast carcinoma. J Pathol 1992, 166:13-18. 10.1002/path.1711660104, 1538271.